Cranbrook Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Cranbrook Wealth Management’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-66	Closed	-$74	–	395
2025 Q2	$74	Hold	66	–	–	﹤0.01%	397
2025 Q1	$84	Hold	66	–	–	﹤0.01%	420
2024 Q4	$150	Buy	+66	New	+$122	﹤0.01%	400
2024 Q3	–	Sell	-67	Closed	-$339	–	377
2024 Q2	$339	Hold	67	–	–	﹤0.01%	308
2024 Q1	$565	Buy	+67	New	+$368	﹤0.01%	288

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

Cranbrook Wealth Management's BCLI Position: Q3 2025 in Review

Cranbrook Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 66 shares — an estimated $74 sold.

Cranbrook Wealth Management first reported a position in BCLI in Q1 2024 and held it in 5 quarters. The position peaked at $565 in Q1 2024. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Cranbrook Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Cranbrook Wealth Management sold 66 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $74.
Cranbrook Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2024 and held it in 5 quarters.
Cranbrook Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $565 in Q1 2024.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Cranbrook Wealth Management's 13F filing for Q3 2025, filed 14 Oct 2025.